Susquehanna International Group
CLDX icon

Susquehanna International Group’s Celldex Therapeutics CLDX Stock Holding History

Susquehanna International Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$818K Buy
25,800
+16,200
+169% +$442K ﹤0.01% 8420
2025
Q4 		$261K Sell
9,600
-74,300
-89% -$1.96M ﹤0.01% 10284
2025
Q3 		$2.17M Sell
83,900
-13,900
-14% -$322K ﹤0.01% 5596
2025
Q2 		$1.99M Buy
97,800
+86,300
+750% +$1.68M ﹤0.01% 5791
2025
Q1 		$209K Sell
11,500
-43,900
-79% -$981K ﹤0.01% 10843
2024
Q4 		$1.4M Sell
55,400
-50,600
-48% -$1.37M ﹤0.01% 6121
2024
Q3 		$3.6M Buy
106,000
+2,100
+2% +$80K ﹤0.01% 4204
2024
Q2 		$3.85M Sell
103,900
-47,900
-32% -$1.81M ﹤0.01% 3876
2024
Q1 		$6.37M Buy
151,800
+30,200
+25% +$1.24M ﹤0.01% 3239
2023
Q4 		$4.82M Sell
121,600
-4,200
-3% -$124K ﹤0.01% 3760
2023
Q3 		$3.46M Buy
125,800
+61,400
+95% +$1.92M ﹤0.01% 4138
2023
Q2 		$2.19M Sell
64,400
-1,300
-2% -$43.8K ﹤0.01% 4971
2023
Q1 		$2.36M Sell
65,700
-83,100
-56% -$3.59M ﹤0.01% 4798
2022
Q4 		$6.63M Sell
148,800
-500
-0.3% -$17.9K ﹤0.01% 2813
2022
Q3 		$4.2M Sell
149,300
-71,100
-32% -$2.18M ﹤0.01% 3433
2022
Q2 		$5.94M Buy
220,400
+53,200
+32% +$1.54M ﹤0.01% 2910
2022
Q1 		$5.7M Sell
167,200
-28,300
-14% -$905K ﹤0.01% 3418
2021
Q4 		$7.55M Buy
195,500
+6,900
+4% +$301K ﹤0.01% 3097
2021
Q3 		$10.2M Buy
188,600
+6,700
+4% +$314K ﹤0.01% 2842
2021
Q2 		$6.08M Sell
181,900
-20,200
-10% -$554K ﹤0.01% 3663
2021
Q1 		$4.16M Buy
202,100
+37,900
+23% +$870K ﹤0.01% 4264
2020
Q4 		$2.88M Buy
164,200
+94,700
+136% +$1.7M ﹤0.01% 4376
2020
Q3 		$1.03M Sell
69,500
-44,100
-39% -$517K ﹤0.01% 6042
2020
Q2 		$1.48M Buy
113,600
+100,200
+748% +$444K ﹤0.01% 5064
2020
Q1 		$22K Buy
+13,400
New +$30.3K ﹤0.01% 9914
2019
Q4 		– Sell
-29,600
Closed -$63K – 9788
2019
Q3 		$63K Buy
29,600
+3,800
+15% +$8.79K ﹤0.01% 9714
2019
Q2 		$69K Buy
+25,800
New +$87.6K ﹤0.01% 9750
2018
Q2 		– Sell
-12,160
Closed -$425K – 9663
2018
Q1 		$425K Buy
12,160
+3,660
+43% +$142K ﹤0.01% 6965
2017
Q4 		$362K Buy
8,500
+1,480
+21% +$63.4K ﹤0.01% 7243
2017
Q3 		$301K Buy
7,020
+2,960
+73% +$111K ﹤0.01% 7386
2017
Q2 		$150K Sell
4,060
-1,853
-31% -$82K ﹤0.01% 8494
2017
Q1 		$320K Sell
5,913
-9,787
-62% -$510K ﹤0.01% 7240
2016
Q4 		$834K Sell
15,700
-8,387
-35% -$477K ﹤0.01% 5910
2016
Q3 		$1.46M Buy
24,087
+9,494
+65% +$591K ﹤0.01% 4099
2016
Q2 		$961K Sell
14,593
-254
-2% -$16.1K ﹤0.01% 4958
2016
Q1 		$842K Sell
14,847
-32,380
-69% -$3.64M ﹤0.01% 5432
2015
Q4 		$11.1M Sell
47,227
-5,700
-11% -$1.24M 0.01% 1656
2015
Q3 		$8.37M Sell
52,927
-4,146
-7% -$1.17M ﹤0.01% 2037
2015
Q2 		$21.6M Sell
57,073
-13,080
-19% -$5.19M 0.01% 1242
2015
Q1 		$29.3M Sell
70,153
-15,654
-18% -$5.6M 0.01% 953
2014
Q4 		$23.5M Buy
85,807
+14,620
+21% +$3.63M 0.01% 1227
2014
Q3 		$13.8M Sell
71,187
-13,473
-16% -$2.94M 0.01% 1762
2014
Q2 		$20.7M Buy
84,660
+20,793
+33% +$4.69M 0.01% 1370
2014
Q1 		$16.9M Buy
63,867
+19,834
+45% +$7.59M 0.01% 1428
2013
Q4 		$16M Buy
44,033
+18,320
+71% +$7.06M 0.01% 1592
2013
Q3 		$13.7M Buy
25,713
+1,400
+6% +$480K 0.01% 1564
2013
Q2 		$5.69M Buy
+24,313
New +$4.79M ﹤0.01% 2453

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Susquehanna International Group's CLDX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 35,948 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #7542 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CLDX as recently as Q3 2025.

Susquehanna International Group first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $13.3M in Q4 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Susquehanna International Group held 35,948 shares of Celldex Therapeutics worth $1.14M as of Q1 2026.
  • Celldex Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7542 holding.
  • Susquehanna International Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Susquehanna International Group's Celldex Therapeutics position peaked at $13.3M in Q4 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.